Cargando…

What matters most to patients with multiple myeloma? A Pan-European patient preference study

INTRODUCTION: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Morgan, Kate, Plate, Ananda, De Ronne, Chris, Verschueren, Margaux, Schoefs, Elise, Vanhellemont, Anneleen, Delforge, Michel, Schjesvold, Fredrik, Cabezudo, Elena, Vandebroek, Martina, Stevens, Hilde, Simoens, Steven, Huys, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745810/
https://www.ncbi.nlm.nih.gov/pubmed/36523996
http://dx.doi.org/10.3389/fonc.2022.1027353
_version_ 1784849229257113600
author Janssens, Rosanne
Lang, Tamika
Vallejo, Ana
Galinsky, Jayne
Morgan, Kate
Plate, Ananda
De Ronne, Chris
Verschueren, Margaux
Schoefs, Elise
Vanhellemont, Anneleen
Delforge, Michel
Schjesvold, Fredrik
Cabezudo, Elena
Vandebroek, Martina
Stevens, Hilde
Simoens, Steven
Huys, Isabelle
author_facet Janssens, Rosanne
Lang, Tamika
Vallejo, Ana
Galinsky, Jayne
Morgan, Kate
Plate, Ananda
De Ronne, Chris
Verschueren, Margaux
Schoefs, Elise
Vanhellemont, Anneleen
Delforge, Michel
Schjesvold, Fredrik
Cabezudo, Elena
Vandebroek, Martina
Stevens, Hilde
Simoens, Steven
Huys, Isabelle
author_sort Janssens, Rosanne
collection PubMed
description INTRODUCTION: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods for quantifying patients’ preferences. METHODS: A survey incorporating DCE and SW was disseminated among European MM patients. The survey included attributes and levels informed by a previous qualitative study with 24 MM patients. Latent class and mixed logit models were used to estimate the DCE attribute weights and descriptive analyses were performed to derive SW weights. MM patients and patient organisations provided extensive feedback during survey development. RESULTS: 393 MM patients across 21 countries completed the survey (M (years since diagnosis)=6; M (previous therapies)=3). Significant differences (p<.01) between participants’ attribute weights were revealed depending on participants’ prior therapy experience, and their experience with side-effects and symptoms. Multivariate analyses showed that participants across the three MM patient classes identified via the latent class model differed regarding their past number of therapies (F=4.772, p=.009). Patients with the most treatments (class 1) and those with the least treatments (class 3) attached more value to life expectancy versus quality of life-related attributes such as pain, mobility and thinking problems. Conversely, patients with intermediary treatment experience (class 2) attached more value to quality of life-related attributes versus life expectancy. Participants highlighted the difficulty of trading-off between life expectancy and quality of life and between physical and mental health. Participants expressed a need for greater psychological support to cope with their symptoms, treatment side-effects, and uncertainties. With respect to patients’ preferences for the DCE or SW questions, 42% had no preference, 32% preferred DCE, and 25% preferred SW. CONCLUSIONS: Quality of life-related attributes affecting MM patients’ physical, mental and psychological health such as pain, mobility and thinking problems were considered very important to MM patients, next to life expectancy. This underscores a need to include such attributes in decision-making by healthcare stakeholders involved in MM drug development, evidence generation, evaluation, and clinical practice. This study highlights DCE as the preferred methodology for understanding relative attribute weights from a patient’s perspective.
format Online
Article
Text
id pubmed-9745810
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97458102022-12-14 What matters most to patients with multiple myeloma? A Pan-European patient preference study Janssens, Rosanne Lang, Tamika Vallejo, Ana Galinsky, Jayne Morgan, Kate Plate, Ananda De Ronne, Chris Verschueren, Margaux Schoefs, Elise Vanhellemont, Anneleen Delforge, Michel Schjesvold, Fredrik Cabezudo, Elena Vandebroek, Martina Stevens, Hilde Simoens, Steven Huys, Isabelle Front Oncol Oncology INTRODUCTION: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods for quantifying patients’ preferences. METHODS: A survey incorporating DCE and SW was disseminated among European MM patients. The survey included attributes and levels informed by a previous qualitative study with 24 MM patients. Latent class and mixed logit models were used to estimate the DCE attribute weights and descriptive analyses were performed to derive SW weights. MM patients and patient organisations provided extensive feedback during survey development. RESULTS: 393 MM patients across 21 countries completed the survey (M (years since diagnosis)=6; M (previous therapies)=3). Significant differences (p<.01) between participants’ attribute weights were revealed depending on participants’ prior therapy experience, and their experience with side-effects and symptoms. Multivariate analyses showed that participants across the three MM patient classes identified via the latent class model differed regarding their past number of therapies (F=4.772, p=.009). Patients with the most treatments (class 1) and those with the least treatments (class 3) attached more value to life expectancy versus quality of life-related attributes such as pain, mobility and thinking problems. Conversely, patients with intermediary treatment experience (class 2) attached more value to quality of life-related attributes versus life expectancy. Participants highlighted the difficulty of trading-off between life expectancy and quality of life and between physical and mental health. Participants expressed a need for greater psychological support to cope with their symptoms, treatment side-effects, and uncertainties. With respect to patients’ preferences for the DCE or SW questions, 42% had no preference, 32% preferred DCE, and 25% preferred SW. CONCLUSIONS: Quality of life-related attributes affecting MM patients’ physical, mental and psychological health such as pain, mobility and thinking problems were considered very important to MM patients, next to life expectancy. This underscores a need to include such attributes in decision-making by healthcare stakeholders involved in MM drug development, evidence generation, evaluation, and clinical practice. This study highlights DCE as the preferred methodology for understanding relative attribute weights from a patient’s perspective. Frontiers Media S.A. 2022-11-29 /pmc/articles/PMC9745810/ /pubmed/36523996 http://dx.doi.org/10.3389/fonc.2022.1027353 Text en Copyright © 2022 Janssens, Lang, Vallejo, Galinsky, Morgan, Plate, De Ronne, Verschueren, Schoefs, Vanhellemont, Delforge, Schjesvold, Cabezudo, Vandebroek, Stevens, Simoens and Huys https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Janssens, Rosanne
Lang, Tamika
Vallejo, Ana
Galinsky, Jayne
Morgan, Kate
Plate, Ananda
De Ronne, Chris
Verschueren, Margaux
Schoefs, Elise
Vanhellemont, Anneleen
Delforge, Michel
Schjesvold, Fredrik
Cabezudo, Elena
Vandebroek, Martina
Stevens, Hilde
Simoens, Steven
Huys, Isabelle
What matters most to patients with multiple myeloma? A Pan-European patient preference study
title What matters most to patients with multiple myeloma? A Pan-European patient preference study
title_full What matters most to patients with multiple myeloma? A Pan-European patient preference study
title_fullStr What matters most to patients with multiple myeloma? A Pan-European patient preference study
title_full_unstemmed What matters most to patients with multiple myeloma? A Pan-European patient preference study
title_short What matters most to patients with multiple myeloma? A Pan-European patient preference study
title_sort what matters most to patients with multiple myeloma? a pan-european patient preference study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745810/
https://www.ncbi.nlm.nih.gov/pubmed/36523996
http://dx.doi.org/10.3389/fonc.2022.1027353
work_keys_str_mv AT janssensrosanne whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT langtamika whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT vallejoana whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT galinskyjayne whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT morgankate whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT plateananda whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT deronnechris whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT verschuerenmargaux whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT schoefselise whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT vanhellemontanneleen whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT delforgemichel whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT schjesvoldfredrik whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT cabezudoelena whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT vandebroekmartina whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT stevenshilde whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT simoenssteven whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy
AT huysisabelle whatmattersmosttopatientswithmultiplemyelomaapaneuropeanpatientpreferencestudy